Ultrashape.com., September 17, 2008
Ultrashape Introduces a Faster Treatment and Better Patient Experience at 2008 EADV
| Thirty Five Percent Reduction in Treatment Time, Shorter Intervals Between Treatments and Improved Transducer Make the UltraShape(R) Non-Invasive Fat Reduction and Body Contouring System a More Compelling Option
YOQNEAM, Israel and SAN RAMON, California
UltraShape, a global leader in non-invasive fat reduction and body contouring, will introduce its latest software and new transducer at the upcoming 2008 European Academy of Dermatology and Venereology (EADV) annual meeting in Paris. The upgraded software and new transducer offer new features that reduce treatment time, lower treatment cost and enhance the UltraShape® experience for both physicians and patients.
The new UltraShape solution makes it possible to reduce average treatment time to between 40 and 60 minutes, depending on the treatment area, a reduction of about 35% over prior versions.
In addition, Clinical studies conducted in France, Canada and Israel demonstrated that three-successive UltraShape treatments at two-week intervals are safe and effective, and show significant treatment area reduction, which means that the three treatment series can be completed within one month without compromising results.
Lastly, UltraShape now offers an improved transducer that emits 50 percent more ultrasonic pulses for the same price as the previous one, thus reducing treatment cost significantly.
"The introduction of these features mark a significant improvement to the UltraShape system," said Montreal-based plastic surgeon, Dr. Arie Benchetrit. "We as physicians along with our patients welcome shorter treatment time, making UltraShape an even more convenient 'walk-in, walk-out procedure.' Moreover, the reduced treatment time and ability to complete a three-treatment series in one month make the UltraShape solution more convenient for patients while at the same time significantly reducing the baseline costs." Added Dr. Benchetrit.
"We are constantly listening to our customers and looking to improve and enhance our scientifically and clinically proven non-invasive fat reduction and body contouring platform," said UltraShape CEO, Assaf Eyal. "These significant improvements to both software and transducer are in direct response to customer feedback which strengthen our alliances with treating physicians, and further enhance the UltraShape experience for both clinicians and patients across the globe."
About the UltraShape® Contour I
The UltraShape Contour I system, which is authorized for marketing outside the U.S., incorporates patented non-thermal selective focused ultrasound technology. Contour I, is the first scientifically and clinically proven non-invasive fat reduction and body contouring device for both men and women. The device is designed to produce mechanical, non-thermal, acoustic effects which target and selectively disrupt fat cells, leaving surrounding critical structures such as skin, blood vessels, nerves, and connective tissue intact.
The UltraShape procedure is available in 57 countries and over 100,000 patient treatments have been performed worldwide with high patient satisfaction. The UltraShape procedure is guided by proprietary real-time tracking and guidance technology designed to deliver smooth, uniform body contouring results. The software provides a pre-determined treatment algorithm designed to minimize risk of contour irregularities, a common side effect of liposuction. The UltraShape procedure is performed during a convenient, "walk-in, walk-out" session carried out in an office-based environment; it requires no anesthesia or sedation. After treatment, patients immediately resume their daily routines with no need for maintenance treatments.
The UltraShape Contour I received the CE Mark in 2005 and a medical device license from Health Canada in 2007. The Contour I system is not available for sale in the U.S. and the Contour Plus system is an investigational product limited by U.S. law to investigational use only.
UltraShape is redefining aesthetic medicine by developing, manufacturing and marketing innovative non-invasive technologies for body contouring. The company is dedicated to providing clinically proven safe and effective solutions that enhance the lives of patients worldwide. The UltraShape proprietary non-invasive body contouring technology is based on focused ultrasound that targets and selectively disrupts fat cells without affecting surrounding structures. Founded in 2000, UltraShape is a privately held and venture backed company. The UltraShape system is not approved by the FDA for marketing in the United States.
For more information visit www.ultrashape.com.
UltraShape NA Inc.